{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:20:29Z","timestamp":1770988829308,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T00:00:00Z","timestamp":1598745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T00:00:00Z","timestamp":1598745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","award":["Research grant from the Faculty of pharmacy"],"award-info":[{"award-number":["Research grant from the Faculty of pharmacy"]}],"id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00520-020-05703-7","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:05:08Z","timestamp":1598742308000},"page":"2083-2091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of mannitol on acute kidney injury induced by cisplatin"],"prefix":"10.1007","volume":"29","author":[{"given":"Anne-Marie","family":"B\u00e9gin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Lawrence","family":"Monfette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9tienne","family":"Boudrias-Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmie","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Samouelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Chagnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Andr\u00e9e","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Letarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-0944","authenticated-orcid":false,"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"5703_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115\u2013124","journal-title":"Am J Med Sci"},{"key":"5703_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609\u2013619","journal-title":"Oncologist"},{"key":"5703_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994\u20131007","journal-title":"Kidney Int"},{"key":"5703_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","volume":"61","author":"V Launay-Vacher","year":"2008","unstructured":"Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903\u2013909","journal-title":"Cancer Chemother Pharmacol"},{"key":"5703_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1177\/1060028014533303","volume":"48","author":"KP Morgan","year":"2014","unstructured":"Morgan KP, Snavely AC, Wind LS, Buie LW, Grilley-Olson J, Walko CM, Weiss J (2014) Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother 48:863\u2013869","journal-title":"Ann Pharmacother"},{"key":"5703_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jcpt.12509","volume":"42","author":"CM Mach","year":"2017","unstructured":"Mach CM, Kha C, Nguyen D, Shumway J, Meaders KM, Ludwig M, Williams-Brown MY, Anderson ML (2017) A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J Clin Pharm Ther 42:286\u2013291","journal-title":"J Clin Pharm Ther"},{"key":"5703_CR7","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490\u20132518","journal-title":"Toxins (Basel)"},{"key":"5703_CR8","first-page":"73","volume":"65","author":"S Ostrow","year":"1981","unstructured":"Ostrow S, Egorin MJ, Hahn D et al (1981) High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73\u201378","journal-title":"Cancer Treat Rep"},{"key":"5703_CR9","first-page":"375","volume":"61","author":"JM Ward","year":"1977","unstructured":"Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats. Cancer Treat Rep 61:375\u2013379","journal-title":"Cancer Treat Rep"},{"key":"5703_CR10","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J","volume":"39","author":"DM Hayes","year":"1977","unstructured":"Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372\u20131381","journal-title":"Cancer"},{"key":"5703_CR11","first-page":"31","volume":"66","author":"M Al-Sarraf","year":"1982","unstructured":"Al-Sarraf M, Fletcher W, Oishi N et al (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31\u201335","journal-title":"Cancer Treat Rep"},{"key":"5703_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-003-0620-1","volume":"52","author":"JT Santoso","year":"2003","unstructured":"Santoso JT, Lucci JA 3rd, Coleman RL et al (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13\u201318","journal-title":"Cancer Chemother Pharmacol"},{"key":"5703_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1078155209346071","volume":"16","author":"L Leu","year":"2010","unstructured":"Leu L, Baribeault D (2010) A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract 16:167\u2013171","journal-title":"J Oncol Pharm Pract"},{"key":"5703_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1345\/aph.1Q333","volume":"46","author":"KP Morgan","year":"2012","unstructured":"Morgan KP, Buie LW, Savage SW (2012) The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother 46:276\u2013281","journal-title":"Ann Pharmacother"},{"key":"5703_CR15","doi-asserted-by":"crossref","unstructured":"McKibbin T, Cheng LL, Kim S et al. (2015) Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer","DOI":"10.1007\/s00520-015-2978-0"},{"key":"5703_CR16","doi-asserted-by":"crossref","unstructured":"Williams RP, Jr., Ferlas BW, Morales PC, Kurtzweil AJ (2016) Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J Oncol Pharm Pract","DOI":"10.1177\/1078155216656927"},{"key":"5703_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/1078155218771461","volume":"25","author":"P Dhillon","year":"2019","unstructured":"Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P (2019) A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. J Oncol Pharm Pract 25:875\u2013883","journal-title":"J Oncol Pharm Pract"},{"key":"5703_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1042\/cs1010173","volume":"101","author":"DN Lobo","year":"2001","unstructured":"Lobo DN, Stanga Z, Simpson JA et al (2001) Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w\/v) saline and 5% (w\/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci (Lond) 101:173\u2013179","journal-title":"Clin Sci (Lond)"},{"key":"5703_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/BF02897230","volume":"26","author":"M Dumas","year":"1990","unstructured":"Dumas M, de Gislain C, d\u2019Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N (1990) Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 26:278\u2013282","journal-title":"Cancer Chemother Pharmacol"},{"key":"5703_CR20","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, U.S. Departement of Health and Human services, National Institutes of Health and National Cancer Institute. In. 2010"},{"key":"5703_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/sim.4780081009","volume":"8","author":"A Cnaan","year":"1989","unstructured":"Cnaan A, Ryan L (1989) Survival analysis in natural history studies of disease. Stat Med 8:1255\u20131268","journal-title":"Stat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T23:12:14Z","timestamp":1630278734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,30]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5703"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05703-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,30]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval by the CHUM research and ethics committee was obtained prior to data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AM B\u00e9gin, ML Monfette, E Boudrias-Dalle, E Lavall\u00e9, V Samouelian, D Souli\u00e8res, M. Chagnon, and N Letarte declare that they have no conflict of interest. MA Fournier reports personal fees from Amgen and Pfizer outside the submitted work. JP Adam reports personal fees from Amgen, Novartis, Abbvie, Sandoz, and Celgene outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We have full control of all primary data and we agree to allow the journal to review our data if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}